Goeckerman therapy versus biologics in the treatment of psoriasis

Journal of the American Academy of Dermatology

Volumn 62, Issue 3, 2010, Pages 516-517

  Menter, Alan ^a  

^a BAYLOR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ARTICLE; BIOLOGICAL THERAPY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; GOECKERMAN METHOD; HUMAN; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; REFRACTORY PERIOD; REMISSION; SOCIOECONOMICS;

ANTIBODIES, MONOCLONAL; COAL TAR; COMBINED MODALITY THERAPY; HUMANS; KERATOLYTIC AGENTS; PSORIASIS; ULTRAVIOLET THERAPY;

EID: 76249094900     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.06.003     Document Type: Article

References (3)

1. Serrao R., and Davis M.D. Goeckerman treatment for remission of psoriasis refractory to biologic therapy. J Am Acad Dermatol 60 (2009) 348-349
2. Menter A., Feldman S.R., Weinstein G.D., Papp K., Evans R., Guzzo C., et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56 (2007) 31 e1-15. Epub 2006 Sep 6
3. Menter A., Tyring S.K., Gordon K., Kimball A.B., Leonardi C.L., Langley R.G., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58 (2008) 106-115 Epub 2007 Oct 23